Premal H. Thaker, MD,MS is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology; Director, Gynecological Oncology Clinical Research; Interim Chief, Division of Gynecologic Oncology.
The panel reflects on the most important unanswered questions and future directions in endometrial cancer. Dr. Konecny highlights the promise of molecularly stratified treatment approaches targeting HER2, TROP2, B7-H4, and hormonal signaling pathways, drawing parallels to successes achieved in breast cancer.
Premal H. Thaker, MD, MS, discusses the phase 2 MAESTRA 1 trial (NCT07023627) in platinum-resistant ovarian cancer.
Dr. Thaker reviews the immune-related adverse event profile associated with checkpoint inhibitor therapy in endometrial cancer, describing the most commonly encountered toxicities in clinical practice, including hypothyroidism, hyperthyroidism, colitis, and arthralgias.
Dr. Redfern provides a detailed, clinically practical overview of mismatch repair and microsatellite instability testing in endometrial cancer, explaining the mechanistic differences between immunohistochemistry—which assesses protein expression of MLH1, PMS2, MSH2, and MSH6—and next-generation sequencing or PCR-based microsatellite instability testing.
The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline checkpoint inhibitor–based therapy.
Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.
New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.
Dr. Konecny reviews the design and key efficacy findings of the RUBY trial, the first large randomized study to evaluate dostarlimab in combination with carboplatin and paclitaxel as frontline therapy for advanced or recurrent endometrial cancer. He describes the eligibility criteria, dosing schedule, and the striking outcomes observed in both mismatch repair–deficient and mismatch repair–proficient patient populations, including a approximately 70% risk reduction in progression-free survival in the deficient group and a statistically significant 25% risk reduction in the proficient group. Dr. Wenham and Dr. Konecny also contrast the RUBY and NRG-GY018 trial designs. Dr. Redfern then addresses how these results translate to real-world populations, citing evidence presented at ASCO 2025 demonstrating comparable outcomes, and shares her own clinical experience incorporating dostarlimab into routine practice.
Moderator Robert M. Wenham, MD, MS, opens by welcoming panelists Premal H. Thaker, MD, MS, Tiffany M. Redfern, MD, FACOG, and Gottfried E. Konecny, MD, before setting the stage for the discussion. Dr. Thaker reviews the pre-2024 treatment landscape in advanced and recurrent endometrial cancer, including the establishment of paclitaxel plus carboplatin as standard-of-care chemotherapy through GOG 209. She then outlines the pivotal shift brought about by the addition of immune checkpoint inhibitors to chemotherapy, highlighting the RUBY, NRG-GY018, and DUO-E trials and summarizing the FDA approvals that emerged from each. The panel briefly distinguishes the indications across regimens, noting that approval for the durvalumab-plus-olaparib combination was limited to patients with mismatch repair–deficient disease, setting the stage for deeper discussion of individual trial data.
Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.
Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.
Premal H. Thaker, MD, MS, discusses the safety of intraperitoneal administration of IMNN-001 plus neoadjuvant chemotherapy in epithelial ovarian cancer.
Premal H. Thaker, MD, discusses safety and efficacy data for IMNN-001 plus neoadjuvant chemotherapy in newly diagnosed ovarian cancer.
Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.
Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, exploring its implications for treatment approaches in advanced endometrial cancer, how to integrate T-DXd into treatment algorithms, patient selection criteria, and which patients are most likely to benefit from this therapy compared to lenvatinib/pembrolizumab.
Panelists discuss emerging data from ongoing trials evaluating innovative combination strategies for endometrial cancer, including insights from the LEAP trial (pembrolizumab + lenvatinib) and the KEYNOTE-B21 trial (pembrolizumab + chemotherapy with or without radiotherapy). They also address treatment considerations for patients with sentinel lymph node–positive disease.
Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.
Panelists discuss recent updates from the DUO-E trial, highlighting key efficacy and safety data that led to the FDA’s approval of durvalumab for endometrial cancer while examining how this new indication influences treatment strategies for advanced or recurrent cases.
Panelists review available treatment options for recurrent endometrial cancer, discussing their typical treatment approaches and the factors influencing treatment selection. Panelists also address insights from the RUBY trial, its updates, and the expanded FDA indication for dostarlimab, including the implications of these developments on treatment strategies and the potential benefits and challenges of broader use in patients.
Panelists discuss their approach to biomarker testing in advanced endometrial cancer, including the timing and types of testing performed, the specific biomarkers assessed (such as mismatch repair/microsatellite instability, POLE, and TP53), and how these results inform treatment decisions.
Panelists discuss the integration of tisotumab vedotin into ovarian cancer therapy, covering its role in treatment approaches, patient selection, adverse event management, clinical pearls, challenges in practice, and the implications of the drug’s payload on treatment efficacy.
Panelists discuss key findings from the KEYNOTE-A18 trial, which evaluated pembrolizumab in combination with chemoradiotherapy for high-risk locally advanced cervical cancer, highlighting the implications for treatment approaches in this patient population.
Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.
Panelists discuss the recent tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) based on findings from the DESTINY-PanTumor02 trial, its potential impact on treating advanced ovarian cancer given HER2 data, and how T-DXd may fit into the current treatment algorithm for ovarian cancer.
Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.
Panelists discuss how emerging maintenance strategies for advanced/metastatic disease increasingly focus on novel combination approaches, including immunotherapy combinations with PARP inhibitors (rucaparib + nivolumab), anti-angiogenic agents (atezolizumab + bevacizumab), and dual targeted therapy (olaparib + cediranib), with ongoing evaluation of optimal patient selection and sequencing in the treatment paradigm.
Panelists explore emerging combination therapies in maintenance treatment for advanced ovarian cancer, including rucaparib + nivolumab; atezolizumab + bevacizumab; and olaparib + cediranib, also discussing how these strategies fit into the current treatment paradigm and in which patient populations they may be considered.
Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.
October 14th 2024
October 28th 2024
